170 related articles for article (PubMed ID: 34934147)
21. Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?
Bonda A; Punatar S; Gokarn A; Mohite A; Shanmugam K; Nayak L; Bopanna M; Cheriyalinkal Parambil B; Khattry N
Bone Marrow Transplant; 2018 Nov; 53(11):1487-1489. PubMed ID: 29884853
[No Abstract] [Full Text] [Related]
22. Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia.
Vaikari VP; Park M; Keossayan L; MacKay JA; Alachkar H
Nanomedicine; 2020 Oct; 29():102236. PubMed ID: 32535112
[TBL] [Abstract][Full Text] [Related]
23. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.
Angelova E; Audette C; Kovtun Y; Daver N; Wang SA; Pierce S; Konoplev SN; Khogeer H; Jorgensen JL; Konopleva M; Zweidler-McKay PA; Medeiros LJ; Kantarjian HM; Jabbour EJ; Khoury JD
Haematologica; 2019 Apr; 104(4):749-755. PubMed ID: 30361418
[TBL] [Abstract][Full Text] [Related]
24. Fundus Abnormalities in Acute Leukemia.
Antheriou MC; Jacquier P; Malclès A
JAMA Ophthalmol; 2020 Mar; 138(3):e190934. PubMed ID: 32163122
[No Abstract] [Full Text] [Related]
25. Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes.
Kang LC; Dunphy CH
Arch Pathol Lab Med; 2006 Feb; 130(2):153-7. PubMed ID: 16454553
[TBL] [Abstract][Full Text] [Related]
26. CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity.
Husak Z; Dworzak MN
Cell Death Dis; 2012 Nov; 3(11):e425. PubMed ID: 23152061
[TBL] [Abstract][Full Text] [Related]
27. Detection of occult cerebrospinal fluid involvement during maintenance therapy identifies a group of children with acute lymphoblastic leukemia at high risk for relapse.
Martínez-Laperche C; Gómez-García AM; Lassaletta Á; Moscardó C; Vivanco JL; Molina J; Fuster JL; Couselo JM; de Toledo JS; Bureo E; Madero L; Ramírez M
Am J Hematol; 2013 May; 88(5):359-64. PubMed ID: 23468276
[TBL] [Abstract][Full Text] [Related]
28. Relapsed T Cell ALL: Current Approaches and New Directions.
McMahon CM; Luger SM
Curr Hematol Malig Rep; 2019 Apr; 14(2):83-93. PubMed ID: 30880359
[TBL] [Abstract][Full Text] [Related]
29. Targeting FoxM1 transcription factor in T-cell acute lymphoblastic leukemia cell line.
Tüfekçi Ö; Yandım MK; Ören H; İrken G; Baran Y
Leuk Res; 2015 Mar; 39(3):342-7. PubMed ID: 25557384
[TBL] [Abstract][Full Text] [Related]
30. IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.
González-García S; Mosquera M; Fuentes P; Palumbo T; Escudero A; Pérez-Martínez A; Ramírez M; Corcoran AE; Toribio ML
Blood; 2019 Dec; 134(24):2171-2182. PubMed ID: 31530562
[TBL] [Abstract][Full Text] [Related]
31. TDT (-), KIT (+), CD34 (+), CD99 (+) precursor T lymphoblastic leukemia/lymphoma.
Terada T
Int J Clin Exp Pathol; 2012; 5(2):167-70. PubMed ID: 22400079
[TBL] [Abstract][Full Text] [Related]
32. Production and characterization of monoclonal antibodies against recombinant extracellular domain of CD99.
Thangaretnam KP; Paramasivam OR; Ramanathan P; Gopisetty G; Rajkumar T
Hum Antibodies; 2019; 27(1):69-83. PubMed ID: 30282350
[TBL] [Abstract][Full Text] [Related]
33. Treatment of human T-cell acute lymphoblastic leukemia cells with CFTR inhibitor CFTRinh-172.
Liu M; Liao H; Chen Y; Lin Z; Liu Y; Zhang X; Chan HC; Sun H
Leuk Res; 2019 Nov; 86():106225. PubMed ID: 31541940
[TBL] [Abstract][Full Text] [Related]
34. [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients].
Pan Y; Li GD; Liu WP; Zhang WY; Tang Y; Li FY
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):810-5. PubMed ID: 20193455
[TBL] [Abstract][Full Text] [Related]
35. The meninges enhance leukaemia survival in cerebral spinal fluid.
Basile P; Jonart LM; Ebadi M; Johnson K; Kerfeld M; Gordon PM
Br J Haematol; 2020 May; 189(3):513-517. PubMed ID: 31930492
[TBL] [Abstract][Full Text] [Related]
36. Investigating chemoresistance to improve sensitivity of childhood T-cell acute lymphoblastic leukemia to parthenolide.
Ede BC; Asmaro RR; Moppett JP; Diamanti P; Blair A
Haematologica; 2018 Sep; 103(9):1493-1501. PubMed ID: 29773592
[TBL] [Abstract][Full Text] [Related]
37. Beating the Clock in T-cell Acute Lymphoblastic Leukemia.
Carroll WL; Aifantis I; Raetz E
Clin Cancer Res; 2017 Feb; 23(4):873-875. PubMed ID: 28007775
[TBL] [Abstract][Full Text] [Related]
38. CD44 promotes chemoresistance in T-ALL by increased drug efflux.
Hoofd C; Wang X; Lam S; Jenkins C; Wood B; Giambra V; Weng AP
Exp Hematol; 2016 Mar; 44(3):166-71.e17. PubMed ID: 26708679
[TBL] [Abstract][Full Text] [Related]
39. Prevention of meningeal leukemia. Review of 20 years of research and current recommendations.
Pochedly C
Hematol Oncol Clin North Am; 1990 Oct; 4(5):951-69. PubMed ID: 2262487
[TBL] [Abstract][Full Text] [Related]
40. Biology and pathogenesis of CNS leukemia.
Bleyer WA
Am J Pediatr Hematol Oncol; 1989; 11(1):57-63. PubMed ID: 2712245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
